TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Parkinson's Disease (PD) Drugs Market Research Report 2023

Global Parkinson's Disease (PD) Drugs Market Research Report 2023

  • Category:Life Sciences
  • Published on : 12 December 2022
  • Pages :105
  • Formats:
  • Report Code:SMR-7507074
OfferClick for best price

Best Price: $2320

Parkinson's Disease PD Drugs Market Size, Share 2022


Market Analysis and Insights: Global Parkinson's Disease PD Drugs Market

The global Parkinson's Disease PD Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Parkinson's Disease PD Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Parkinson's Disease PD Drugs market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Parkinson's Disease PD Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Parkinson's Disease PD Drugs market.

Global Parkinson's Disease PD Drugs Scope and Market Size

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.

Due to the COVID-19 pandemic, the global Parkinson's Disease (PD) Drugs market size is estimated to be worth US$ 5492 million in 2022 and is forecast to a readjusted size of US$ 8339.9 million by 2030 with a CAGR of 6.0% during the forecast period 2023-2030. Fully considering the economic change by this health crisis, the Europe Parkinson's Disease (PD) Drugs market is estimated at US$ million in 2023, while the United States and China are forecast to reach US$ million and US$ million by 2030, respectively. The proportion of the United States is % in 2023, while Chinese percentage is %, and it is predicted that China market share will reach % in 2030, trailing a CAGR of % through the analysis period. As for the Europe Parkinson's Disease (PD) Drugs landscape, Germany is projected to reach US$ million by 2030. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.

This report focuses on Parkinson's Disease (PD) Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Parkinson's Disease (PD) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Global Parkinson's Disease (PD) Drugs Market: Segment Analysis

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

Dopamine Agonist

Monoamine Oxidase Inhibitors

Acetylcholinesterase Inhibitors

Glutamate Inhibitors

Segment by Application

Hospital

Family

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

By Company

Boehringer Ingelheim

GlaxoSmithKline

Novartis

Teva Pharmaceutical Industries

AbbVie

Abital Pharma

Addex Therapeutics

Biogen

Eisai

Eli Lilly

F. Hoffmann-La Roche

H. Lundbeck

Impax Laboratories

Kyowa Hakko Kirin

Otsuka Pharmaceutical

Pfizer

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Parkinson's Disease PD Drugs product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Parkinson's Disease PD Drugs, with price, sales, revenue, and global market share of Parkinson's Disease PD Drugs from 2019 to 2022.

Chapter 3, the Parkinson's Disease PD Drugs competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Parkinson's Disease PD Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Parkinson's Disease PD Drugs market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Parkinson's Disease PD Drugs.

Chapter 13, 14, and 15, to describe Parkinson's Disease PD Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Parkinson's Disease PD Drugs Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Parkinson's Disease (PD) Drugs Market Research Report 2023
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 105 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Parkinson's Disease (PD) Drugs Market Overview
1.1 Product Overview and Scope of Parkinson's Disease (PD) Drugs
1.2 Parkinson's Disease (PD) Drugs Segment by Type
1.2.1 Global Parkinson's Disease (PD) Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Dopamine Agonist
1.2.3 Monoamine Oxidase Inhibitors
1.2.4 Acetylcholinesterase Inhibitors
1.2.5 Glutamate Inhibitors
1.3 Parkinson's Disease (PD) Drugs Segment by Application
1.3.1 Global Parkinson's Disease (PD) Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Hospital
1.3.3 Family
1.4 Global Parkinson's Disease (PD) Drugs Market Size Estimates and Forecasts
1.4.1 Global Parkinson's Disease (PD) Drugs Revenue 2017-2030
1.4.2 Global Parkinson's Disease (PD) Drugs Sales 2017-2030
1.4.3 Parkinson's Disease (PD) Drugs Market Size by Region: 2017 Versus 2022 Versus 2030
2 Parkinson's Disease (PD) Drugs Market Competition by Manufacturers
2.1 Global Parkinson's Disease (PD) Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global Parkinson's Disease (PD) Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global Parkinson's Disease (PD) Drugs Average Price by Manufacturers (2017-2023)
2.4 Manufacturers Parkinson's Disease (PD) Drugs Manufacturing Sites, Area Served, Product Type
2.5 Parkinson's Disease (PD) Drugs Market Competitive Situation and Trends
2.5.1 Parkinson's Disease (PD) Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Parkinson's Disease (PD) Drugs Players Market Share by Revenue
2.5.3 Global Parkinson's Disease (PD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Parkinson's Disease (PD) Drugs Retrospective Market Scenario by Region
3.1 Global Parkinson's Disease (PD) Drugs Retrospective Market Scenario in Sales by Region: 2017-2023
3.2 Global Parkinson's Disease (PD) Drugs Retrospective Market Scenario in Revenue by Region: 2017-2023
3.3 North America Parkinson's Disease (PD) Drugs Market Facts & Figures by Country
3.3.1 North America Parkinson's Disease (PD) Drugs Sales by Country
3.3.2 North America Parkinson's Disease (PD) Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Parkinson's Disease (PD) Drugs Market Facts & Figures by Country
3.4.1 Europe Parkinson's Disease (PD) Drugs Sales by Country
3.4.2 Europe Parkinson's Disease (PD) Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Parkinson's Disease (PD) Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Parkinson's Disease (PD) Drugs Sales by Region
3.5.2 Asia Pacific Parkinson's Disease (PD) Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Parkinson's Disease (PD) Drugs Market Facts & Figures by Country
3.6.1 Latin America Parkinson's Disease (PD) Drugs Sales by Country
3.6.2 Latin America Parkinson's Disease (PD) Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Parkinson's Disease (PD) Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Country
3.7.2 Middle East and Africa Parkinson's Disease (PD) Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Parkinson's Disease (PD) Drugs Historic Market Analysis by Type
4.1 Global Parkinson's Disease (PD) Drugs Sales Market Share by Type (2017-2023)
4.2 Global Parkinson's Disease (PD) Drugs Revenue Market Share by Type (2017-2023)
4.3 Global Parkinson's Disease (PD) Drugs Price by Type (2017-2023)
5 Global Parkinson's Disease (PD) Drugs Historic Market Analysis by Application
5.1 Global Parkinson's Disease (PD) Drugs Sales Market Share by Application (2017-2023)
5.2 Global Parkinson's Disease (PD) Drugs Revenue Market Share by Application (2017-2023)
5.3 Global Parkinson's Disease (PD) Drugs Price by Application (2017-2023)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Corporation Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 GlaxoSmithKline Parkinson's Disease (PD) Drugs Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Novartis Parkinson's Disease (PD) Drugs Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Teva Pharmaceutical Industries
6.4.1 Teva Pharmaceutical Industries Corporation Information
6.4.2 Teva Pharmaceutical Industries Description and Business Overview
6.4.3 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Product Portfolio
6.4.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.5 AbbVie
6.5.1 AbbVie Corporation Information
6.5.2 AbbVie Description and Business Overview
6.5.3 AbbVie Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 AbbVie Parkinson's Disease (PD) Drugs Product Portfolio
6.5.5 AbbVie Recent Developments/Updates
6.6 Abital Pharma
6.6.1 Abital Pharma Corporation Information
6.6.2 Abital Pharma Description and Business Overview
6.6.3 Abital Pharma Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Abital Pharma Parkinson's Disease (PD) Drugs Product Portfolio
6.6.5 Abital Pharma Recent Developments/Updates
6.7 Addex Therapeutics
6.6.1 Addex Therapeutics Corporation Information
6.6.2 Addex Therapeutics Description and Business Overview
6.6.3 Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Addex Therapeutics Parkinson's Disease (PD) Drugs Product Portfolio
6.7.5 Addex Therapeutics Recent Developments/Updates
6.8 Biogen
6.8.1 Biogen Corporation Information
6.8.2 Biogen Description and Business Overview
6.8.3 Biogen Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Biogen Parkinson's Disease (PD) Drugs Product Portfolio
6.8.5 Biogen Recent Developments/Updates
6.9 Eisai
6.9.1 Eisai Corporation Information
6.9.2 Eisai Description and Business Overview
6.9.3 Eisai Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 Eisai Parkinson's Disease (PD) Drugs Product Portfolio
6.9.5 Eisai Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Corporation Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 Eli Lilly Parkinson's Disease (PD) Drugs Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 F. Hoffmann-La Roche
6.11.1 F. Hoffmann-La Roche Corporation Information
6.11.2 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Description and Business Overview
6.11.3 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Product Portfolio
6.11.5 F. Hoffmann-La Roche Recent Developments/Updates
6.12 H. Lundbeck
6.12.1 H. Lundbeck Corporation Information
6.12.2 H. Lundbeck Parkinson's Disease (PD) Drugs Description and Business Overview
6.12.3 H. Lundbeck Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 H. Lundbeck Parkinson's Disease (PD) Drugs Product Portfolio
6.12.5 H. Lundbeck Recent Developments/Updates
6.13 Impax Laboratories
6.13.1 Impax Laboratories Corporation Information
6.13.2 Impax Laboratories Parkinson's Disease (PD) Drugs Description and Business Overview
6.13.3 Impax Laboratories Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 Impax Laboratories Parkinson's Disease (PD) Drugs Product Portfolio
6.13.5 Impax Laboratories Recent Developments/Updates
6.14 Kyowa Hakko Kirin
6.14.1 Kyowa Hakko Kirin Corporation Information
6.14.2 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Description and Business Overview
6.14.3 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Product Portfolio
6.14.5 Kyowa Hakko Kirin Recent Developments/Updates
6.15 Otsuka Pharmaceutical
6.15.1 Otsuka Pharmaceutical Corporation Information
6.15.2 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Description and Business Overview
6.15.3 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Product Portfolio
6.15.5 Otsuka Pharmaceutical Recent Developments/Updates
6.16 Pfizer
6.16.1 Pfizer Corporation Information
6.16.2 Pfizer Parkinson's Disease (PD) Drugs Description and Business Overview
6.16.3 Pfizer Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Pfizer Parkinson's Disease (PD) Drugs Product Portfolio
6.16.5 Pfizer Recent Developments/Updates
7 Parkinson's Disease (PD) Drugs Manufacturing Cost Analysis
7.1 Parkinson's Disease (PD) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Parkinson's Disease (PD) Drugs
7.4 Parkinson's Disease (PD) Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Parkinson's Disease (PD) Drugs Distributors List
8.3 Parkinson's Disease (PD) Drugs Customers
9 Parkinson's Disease (PD) Drugs Market Dynamics
9.1 Parkinson's Disease (PD) Drugs Industry Trends
9.2 Parkinson's Disease (PD) Drugs Market Drivers
9.3 Parkinson's Disease (PD) Drugs Market Challenges
9.4 Parkinson's Disease (PD) Drugs Market Restraints
10 Global Market Forecast
10.1 Parkinson's Disease (PD) Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Parkinson's Disease (PD) Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of Parkinson's Disease (PD) Drugs by Type (2023-2030)
10.2 Parkinson's Disease (PD) Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Parkinson's Disease (PD) Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of Parkinson's Disease (PD) Drugs by Application (2023-2030)
10.3 Parkinson's Disease (PD) Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Parkinson's Disease (PD) Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of Parkinson's Disease (PD) Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Parkinson's Disease (PD) Drugs Sales Growth Rate Comparison by Type (2023-2030) & (K Pcs) & (US$ Million)
Table 2. Global Parkinson's Disease (PD) Drugs Sales Growth Rate Comparison by Application (2023-2030) & (K Pcs) & (US$ Million)
Table 3. Global Parkinson's Disease (PD) Drugs Market Size by Region (US$ Million) (2017 VS 2022 VS 2030)
Table 4. Global Parkinson's Disease (PD) Drugs Market Competitive Situation by Manufacturers in 2022
Table 5. Global Parkinson's Disease (PD) Drugs Sales (K Pcs) of Key Manufacturers (2017-2023)
Table 6. Global Parkinson's Disease (PD) Drugs Sales Market Share by Manufacturers (2017-2023)
Table 7. Global Parkinson's Disease (PD) Drugs Revenue (US$ Million) by Manufacturers (2017-2023)
Table 8. Global Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers (2017-2023)
Table 9. Global Market Parkinson's Disease (PD) Drugs Average Price (USD/Pcs) of Key Manufacturers (2017-2023)
Table 10. Manufacturers Parkinson's Disease (PD) Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Parkinson's Disease (PD) Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Parkinson's Disease (PD) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinson's Disease (PD) Drugs as of 2022)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Parkinson's Disease (PD) Drugs Sales by Region (2017-2023) & (K Pcs)
Table 16. Global Parkinson's Disease (PD) Drugs Sales Market Share by Region (2017-2023)
Table 17. Global Parkinson's Disease (PD) Drugs Revenue by Region (2017-2023) & (US$ Million)
Table 18. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Region (2017-2023)
Table 19. North America Parkinson's Disease (PD) Drugs Sales by Country (2017-2023) & (K Pcs)
Table 20. North America Parkinson's Disease (PD) Drugs Sales Market Share by Country (2017-2023)
Table 21. North America Parkinson's Disease (PD) Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 22. North America Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2017-2023)
Table 23. Europe Parkinson's Disease (PD) Drugs Sales by Country (2017-2023) & (K Pcs)
Table 24. Europe Parkinson's Disease (PD) Drugs Sales Market Share by Country (2017-2023)
Table 25. Europe Parkinson's Disease (PD) Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 26. Europe Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2017-2023)
Table 27. Asia Pacific Parkinson's Disease (PD) Drugs Sales by Region (2017-2023) & (K Pcs)
Table 28. Asia Pacific Parkinson's Disease (PD) Drugs Sales Market Share by Region (2017-2023)
Table 29. Asia Pacific Parkinson's Disease (PD) Drugs Revenue by Region (2017-2023) & (US$ Million)
Table 30. Asia Pacific Parkinson's Disease (PD) Drugs Revenue Market Share by Region (2017-2023)
Table 31. Latin America Parkinson's Disease (PD) Drugs Sales by Country (2017-2023) & (K Pcs)
Table 32. Latin America Parkinson's Disease (PD) Drugs Sales Market Share by Country (2017-2023)
Table 33. Latin America Parkinson's Disease (PD) Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 34. Latin America Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2017-2023)
Table 35. Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Country (2017-2023) & (K Pcs)
Table 36. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Market Share by Country (2017-2023)
Table 37. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue by Country (2017-2023) & (US$ Million)
Table 38. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2017-2023)
Table 39. Global Parkinson's Disease (PD) Drugs Sales by Type (2017-2023) & (K Pcs)
Table 40. Global Parkinson's Disease (PD) Drugs Sales Market Share by Type (2017-2023)
Table 41. Global Parkinson's Disease (PD) Drugs Revenue by Type (2017-2023) & (US$ Million)
Table 42. Global Parkinson's Disease (PD) Drugs Revenue Share by Type (2017-2023)
Table 43. Global Parkinson's Disease (PD) Drugs Price by Type (2017-2023) & (USD/Pcs)
Table 44. Global Parkinson's Disease (PD) Drugs Sales (K Pcs) by Application (2017-2023)
Table 45. Global Parkinson's Disease (PD) Drugs Sales Market Share by Application (2017-2023)
Table 46. Global Parkinson's Disease (PD) Drugs Revenue by Application (2017-2023) & (US$ Million)
Table 47. Global Parkinson's Disease (PD) Drugs Revenue Share by Application (2017-2023)
Table 48. Global Parkinson's Disease (PD) Drugs Price by Application (2017-2023) & (USD/Pcs)
Table 49. Boehringer Ingelheim Corporation Information
Table 50. Boehringer Ingelheim Description and Business Overview
Table 51. Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 52. Boehringer Ingelheim Parkinson's Disease (PD) Drugs Product
Table 53. Boehringer Ingelheim Recent Developments/Updates
Table 54. GlaxoSmithKline Corporation Information
Table 55. GlaxoSmithKline Description and Business Overview
Table 56. GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 57. GlaxoSmithKline Parkinson's Disease (PD) Drugs Product
Table 58. GlaxoSmithKline Recent Developments/Updates
Table 59. Novartis Corporation Information
Table 60. Novartis Description and Business Overview
Table 61. Novartis Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 62. Novartis Parkinson's Disease (PD) Drugs Product
Table 63. Novartis Recent Developments/Updates
Table 64. Teva Pharmaceutical Industries Corporation Information
Table 65. Teva Pharmaceutical Industries Description and Business Overview
Table 66. Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 67. Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Product
Table 68. Teva Pharmaceutical Industries Recent Developments/Updates
Table 69. AbbVie Corporation Information
Table 70. AbbVie Description and Business Overview
Table 71. AbbVie Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 72. AbbVie Parkinson's Disease (PD) Drugs Product
Table 73. AbbVie Recent Developments/Updates
Table 74. Abital Pharma Corporation Information
Table 75. Abital Pharma Description and Business Overview
Table 76. Abital Pharma Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 77. Abital Pharma Parkinson's Disease (PD) Drugs Product
Table 78. Abital Pharma Recent Developments/Updates
Table 79. Addex Therapeutics Corporation Information
Table 80. Addex Therapeutics Description and Business Overview
Table 81. Addex Therapeutics Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 82. Addex Therapeutics Parkinson's Disease (PD) Drugs Product
Table 83. Addex Therapeutics Recent Developments/Updates
Table 84. Biogen Corporation Information
Table 85. Biogen Description and Business Overview
Table 86. Biogen Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 87. Biogen Parkinson's Disease (PD) Drugs Product
Table 88. Biogen Recent Developments/Updates
Table 89. Eisai Corporation Information
Table 90. Eisai Description and Business Overview
Table 91. Eisai Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 92. Eisai Parkinson's Disease (PD) Drugs Product
Table 93. Eisai Recent Developments/Updates
Table 94. Eli Lilly Corporation Information
Table 95. Eli Lilly Description and Business Overview
Table 96. Eli Lilly Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 97. Eli Lilly Parkinson's Disease (PD) Drugs Product
Table 98. Eli Lilly Recent Developments/Updates
Table 99. F. Hoffmann-La Roche Corporation Information
Table 100. F. Hoffmann-La Roche Description and Business Overview
Table 101. F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 102. F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Product
Table 103. F. Hoffmann-La Roche Recent Developments/Updates
Table 104. H. Lundbeck Corporation Information
Table 105. H. Lundbeck Description and Business Overview
Table 106. H. Lundbeck Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 107. H. Lundbeck Parkinson's Disease (PD) Drugs Product
Table 108. H. Lundbeck Recent Developments/Updates
Table 109. Impax Laboratories Corporation Information
Table 110. Impax Laboratories Description and Business Overview
Table 111. Impax Laboratories Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 112. Impax Laboratories Parkinson's Disease (PD) Drugs Product
Table 113. Impax Laboratories Recent Developments/Updates
Table 114. Kyowa Hakko Kirin Corporation Information
Table 115. Kyowa Hakko Kirin Description and Business Overview
Table 116. Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 117. Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Product
Table 118. Kyowa Hakko Kirin Recent Developments/Updates
Table 119. Otsuka Pharmaceutical Corporation Information
Table 120. Otsuka Pharmaceutical Description and Business Overview
Table 121. Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 122. Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Product
Table 123. Otsuka Pharmaceutical Recent Developments/Updates
Table 124. Pfizer Corporation Information
Table 125. Pfizer Description and Business Overview
Table 126. Pfizer Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2023)
Table 127. Pfizer Parkinson's Disease (PD) Drugs Product
Table 128. Pfizer Recent Developments/Updates
Table 129. Production Base and Market Concentration Rate of Raw Material
Table 130. Key Suppliers of Raw Materials
Table 131. Parkinson's Disease (PD) Drugs Distributors List
Table 132. Parkinson's Disease (PD) Drugs Customers List
Table 133. Parkinson's Disease (PD) Drugs Market Trends
Table 134. Parkinson's Disease (PD) Drugs Market Drivers
Table 135. Parkinson's Disease (PD) Drugs Market Challenges
Table 136. Parkinson's Disease (PD) Drugs Market Restraints
Table 137. Global Parkinson's Disease (PD) Drugs Sales Forecast by Type (2023-2030) & (K Pcs)
Table 138. Global Parkinson's Disease (PD) Drugs Sales Market Share Forecast by Type (2023-2030)
Table 139. Global Parkinson's Disease (PD) Drugs Revenue Forecast by Type (2023-2030) & (US$ Million)
Table 140. Global Parkinson's Disease (PD) Drugs Revenue Market Share Forecast by Type (2023-2030)
Table 141. Global Parkinson's Disease (PD) Drugs Sales Forecast by Application (2023-2030) & (K Pcs)
Table 142. Global Parkinson's Disease (PD) Drugs Sales Market Share Forecast by Application (2023-2030)
Table 143. Global Parkinson's Disease (PD) Drugs Revenue Forecast by Application (2023-2030) & (US$ Million)
Table 144. Global Parkinson's Disease (PD) Drugs Revenue Market Share Forecast by Application (2023-2030)
Table 145. Global Parkinson's Disease (PD) Drugs Sales Forecast by Region (2023-2030) & (K Pcs)
Table 146. Global Parkinson's Disease (PD) Drugs Sales Market Share Forecast by Region (2023-2030)
Table 147. Global Parkinson's Disease (PD) Drugs Revenue Forecast by Region (2023-2030) & (US$ Million)
Table 148. Global Parkinson's Disease (PD) Drugs Revenue Market Share Forecast by Region (2023-2030)
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Parkinson's Disease (PD) Drugs
Figure 2. Global Parkinson's Disease (PD) Drugs Market Share by Type in 2022 & 2030
Figure 3. Dopamine Agonist Product Picture
Figure 4. Monoamine Oxidase Inhibitors Product Picture
Figure 5. Acetylcholinesterase Inhibitors Product Picture
Figure 6. Glutamate Inhibitors Product Picture
Figure 7. Global Parkinson's Disease (PD) Drugs Market Share by Application in 2022 & 2030
Figure 8. Hospital
Figure 9. Family
Figure 10. Global Parkinson's Disease (PD) Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2030
Figure 11. Global Parkinson's Disease (PD) Drugs Market Size (2017-2030) & (US$ Million)
Figure 12. Global Parkinson's Disease (PD) Drugs Sales (2017-2030) & (K Pcs)
Figure 13. Parkinson's Disease (PD) Drugs Sales Share by Manufacturers in 2022
Figure 14. Global Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers in 2022
Figure 15. The Global 5 and 10 Largest Parkinson's Disease (PD) Drugs Players: Market Share by Revenue in 2022
Figure 16. Parkinson's Disease (PD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2022
Figure 17. Global Parkinson's Disease (PD) Drugs Sales Market Share by Region (2017-2023)
Figure 18. Global Parkinson's Disease (PD) Drugs Sales Market Share by Region in 2022
Figure 19. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Region (2017-2023)
Figure 20. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Region in 2022
Figure 21. U.S. Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 22. Canada Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 23. Germany Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 24. France Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 25. U.K. Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 26. Italy Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 27. Russia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 28. China Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 29. Japan Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 30. South Korea Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 31. India Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 32. Australia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 33. Taiwan Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 34. Indonesia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 35. Thailand Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 36. Malaysia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 37. Philippines Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 38. Vietnam Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 39. Mexico Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 40. Brazil Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 41. Argentina Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 42. Turkey Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 43. Saudi Arabia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 44. UAE Parkinson's Disease (PD) Drugs Revenue Growth Rate (2017-2023) & (US$ Million)
Figure 45. Sales Market Share of Parkinson's Disease (PD) Drugs by Type (2017-2023)
Figure 46. Manufacturing Cost Structure of Parkinson's Disease (PD) Drugs
Figure 47. Manufacturing Process Analysis of Parkinson's Disease (PD) Drugs
Figure 48. Parkinson's Disease (PD) Drugs Industrial Chain Analysis
Figure 49. Channels of Distribution
Figure 50. Distributors Profiles
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount